4basebio UK Societas develops gene therapy technologies and solutions primarily in the United Kingdom. It focuses on the manufacture and supply of synthetic DNA and non-viral nanoparticles for research, therapeutic, and pharmacological use. The company provides services for biotech and pharma customers in the gene therapy and gene vaccine development. It is also involved in the manufacture of enzymes that are used for diagnostic and laboratory test kits. The company was formerly known as 4Basebio SE and changed its name to 4basebio UK Societas in December 2020. 4basebio UK Societas was incorporated in 2020 and is based in Cambridge, United Kingdom.
4basebio PLC’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.